Siemens Healthineers Rallies as RBC Backs Accela Launch, Oddo Trims Target on Ultrasound Retreat
Published on 10/16/2026 at 18:31 | Editorial boerse-global.de
Siemens Healthineers shares drew fresh attention on Friday, climbing 1.0% to EUR 41.21 as investors turned their gaze back to the Erlangen-based medical technology group's product pipeline after months of muted sentiment toward the sector.
The renewed appetite follows an upgrade from RBC, where analyst Natalia Webster lifted her price target to EUR 48 from EUR 45 while reiterating an "Outperform" rating. Webster pointed to the launch of the Accela radiotherapy system as the chief catalyst, arguing the platform underscores both the company's clinical capabilities and its future earnings potential.
That vote of confidence lands against a backdrop of active portfolio surgery. Siemens Healthineers has confirmed it will stop selling general imaging ultrasound systems, including the Acuson Sequoia, Redwood, Juniper and Maple lines, redirecting resources toward more profitable growth areas. The company held no leading position in that conventional segment, where aggressive price competition had been eroding margins, according to a Reuters report. Going forward, the ultrasound division will concentrate on interventional imaging and cardiovascular applications.
The financial weight of that withdrawal has yet to be quantified by management, leaving what amounts to a temporary transparency gap that only hard demand figures for the new systems can close. Whether the strategic cut bears fruit quickly enough to lift the stock clear of its annual low is now the central question for shareholders.
A lucrative market that moves slowly
The decisive variable for the share price's future trajectory is how swiftly Accela's clinical promise converts into actual orders. Advanced radiotherapy is a rich market, but it demands lengthy capital commitments from hospitals and outpatient centers. Investors will need to track how fast the system is ordered and installed over the coming quarters.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Management faces the task of offsetting the loss of established revenue streams. The conversion rate is what matters: can Siemens Healthineers use high-margin innovations like Accela not merely to plug the gap left by the portfolio cleanup, but to accelerate organic growth meaningfully? Fail to prove that soon, and the current share-price enthusiasm could evaporate.
Two analysts, two directions
The analyst community itself is split on the near-term outlook. While RBC moved its target up to EUR 48, Oddo BHF took the opposite path on Monday, cutting its price target to EUR 45 from EUR 47âthough it too kept an "Outperform" rating. That revision lays bare the skepticism surrounding the transition period.
The bull case envisions Accela becoming a new standard in cancer treatment faster than expected. Should the radiotherapy system measurably boost efficiency in clinical practice, major customers could bring orders forward, strengthening the group's pricing power and shifting the product mix decisively toward high-margin segments. The strategic focus would add tailwind in this scenario: by leaving less profitable standard ultrasound behind, sales and development capacity is freed up, potentially lifting the operating margin sooner than the broader market assumes. A confirmation of RBC's thesis could prompt other houses to revise their valuation models upward, propelling the stock toward the EUR 48 target.
The bear case, by contrast, centers on hospital budget discipline. If rising interest rates or healthcare austerity curb spending on capital-intensive equipment, Accela sales could fall well short of expectations. Large medical technology projects are prone to delays, clouding visibility for the months ahead. On top of that, the ultrasound exit threatens to weigh on total revenue before Accela reaches full earning powerâand if the shortfall proves larger than analysts have penciled in, the valuation would come under pressure.
Buyback and balance sheet
Alongside the portfolio reshaping, the company has been repurchasing its own stock. Between September 28 and October 4 inclusive, 49,987 shares were bought back. The group currently carries a market capitalization of EUR 42.82 billion.
Chart levels and the November catalyst
Having recovered roughly 25% from its 52-week low, the stock has distanced itself noticeably from the bottom, yet now faces a directional hurdle. As long as the price holds above recent interim lows, the technical and fundamental recovery structure remains intact, with optimism around the product rollout offering solid support. A sustained break below those levels, however, would threaten a slide back into the prior consolidation zone.
The secondary article notes the shares trading at EUR 41.01 and holding above the 200-day moving average of EUR 38.07âa widely watched trend line whose defense keeps the broader recovery picture alive. A decisive drop beneath it would risk extending the consolidation and testing lower support marks.
Concrete clarity arrives in a matter of weeks. On November 5, 2026, Siemens Healthineers will publish its fourth-quarter results and preliminary figures for the full 2026 fiscal year at 7 a.m., followed by a balance sheet press conference at 10 a.m. and an analyst conference call. That release will show how resilient the group's profitability truly is and whether the ultrasound overhaul can underpin expectations for the coming fiscal year. Until verifiable order intake emerges, the market will keep weighing RBC's optimism against Oddo BHF's caution.
Ad
Siemens Healthineers Stock: New Analysis - 16 October
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
